New V1a receptor antagonist. Part 1. Synthesis and SAR development of urea derivatives was written by Szanto, Gabor;Mako, Attila;Baska, Ferenc;Bozo, Eva;Domany-Kovacs, Katalin;Kurko, Dalma;Cselenyak, Attila;Mohacsi, Reka;Kordas, Krisztina Szondine;Bata, Imre. And the article was included in Bioorganic & Medicinal Chemistry Letters in 2020.Related Products of 5448-43-1 This article mentions the following:
Solid preclin. evidence links vasopressin to social behavior in animals, so, extensive work has been initiated to find new vasopressin V1a receptor antagonists which can improve deteriorated social behavior in humans and can treat the core symptoms of autistic behavior, as well. Our aim was to identify new chem. entities with antagonizing effects on vasopressin V1a receptors. Starting from a moderately potent HTS hit (7), we identified a mol. (49)(I) having nanomolar binding strength and functional activity, which is in the same range as the potency of clin. tested V1a antagonists. In the experiment, the researchers used many compounds, for example, 6-Chloroquinoxaline (cas: 5448-43-1Related Products of 5448-43-1).
6-Chloroquinoxaline (cas: 5448-43-1) belongs to quinoxaline derivatives. Quinoxaline is isomeric with other naphthyridines including quinazoline, phthalazine and cinnoline. The antitumoral properties of quinoxaline compounds have been of interest. Recently, quinoxaline and its analogs have been investigated as the catalyst’s ligands.Related Products of 5448-43-1
Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider